Vir Biotechnology, Inc. (NASDAQ:VIR) Stock Holdings Lessened by Russell Investments Group Ltd.

Russell Investments Group Ltd. cut its stake in shares of Vir Biotechnology, Inc. (NASDAQ:VIR) by 53.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 11,990 shares of the company’s stock after selling 13,654 shares during the quarter. Russell Investments Group Ltd.’s holdings in Vir Biotechnology were worth $121,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of VIR. Signaturefd LLC lifted its position in shares of Vir Biotechnology by 258.5% in the 4th quarter. Signaturefd LLC now owns 3,327 shares of the company’s stock valued at $33,000 after acquiring an additional 2,399 shares in the last quarter. Fifth Third Bancorp boosted its position in shares of Vir Biotechnology by 69.3% in the third quarter. Fifth Third Bancorp now owns 3,941 shares of the company’s stock worth $37,000 after buying an additional 1,613 shares during the period. Federated Hermes Inc. purchased a new position in shares of Vir Biotechnology during the fourth quarter valued at $69,000. PNC Financial Services Group Inc. raised its position in Vir Biotechnology by 99.9% during the third quarter. PNC Financial Services Group Inc. now owns 9,317 shares of the company’s stock valued at $87,000 after buying an additional 4,656 shares during the period. Finally, Sherbrooke Park Advisers LLC purchased a new stake in Vir Biotechnology in the 3rd quarter worth about $99,000. 65.32% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, Director George A. Scangos sold 17,722 shares of Vir Biotechnology stock in a transaction on Monday, February 26th. The shares were sold at an average price of $11.65, for a total value of $206,461.30. Following the transaction, the director now owns 112,989 shares in the company, valued at approximately $1,316,321.85. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, CEO Backer Marianne De sold 72,995 shares of the stock in a transaction that occurred on Wednesday, April 3rd. The stock was sold at an average price of $9.46, for a total transaction of $690,532.70. Following the completion of the sale, the chief executive officer now owns 678,457 shares in the company, valued at approximately $6,418,203.22. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director George A. Scangos sold 17,722 shares of the firm’s stock in a transaction that occurred on Monday, February 26th. The shares were sold at an average price of $11.65, for a total value of $206,461.30. Following the completion of the sale, the director now directly owns 112,989 shares in the company, valued at approximately $1,316,321.85. The disclosure for this sale can be found here. Insiders sold 99,436 shares of company stock valued at $983,659 over the last 90 days. 15.60% of the stock is currently owned by company insiders.

Vir Biotechnology Trading Down 6.3 %

VIR stock opened at $10.65 on Friday. The firm has a market cap of $1.45 billion, a PE ratio of -2.66 and a beta of 0.47. Vir Biotechnology, Inc. has a 1 year low of $7.61 and a 1 year high of $27.48. The company has a fifty day simple moving average of $9.46 and a 200 day simple moving average of $9.77.

Vir Biotechnology (NASDAQ:VIR) last announced its quarterly earnings results on Thursday, May 2nd. The company reported ($0.48) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.99) by $0.51. The company had revenue of $56.38 million during the quarter, compared to analysts’ expectations of $11.71 million. Vir Biotechnology had a negative return on equity of 32.58% and a negative net margin of 677.69%. The business’s quarterly revenue was down 10.5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($1.06) earnings per share. As a group, analysts forecast that Vir Biotechnology, Inc. will post -3.42 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on VIR shares. JPMorgan Chase & Co. upped their target price on Vir Biotechnology from $10.00 to $12.00 and gave the company a “neutral” rating in a report on Friday, May 3rd. HC Wainwright reiterated a “buy” rating and issued a $110.00 target price on shares of Vir Biotechnology in a research report on Tuesday, May 7th. Finally, Needham & Company LLC restated a “buy” rating and set a $15.00 price target on shares of Vir Biotechnology in a report on Friday, May 3rd. Three research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $33.57.

About Vir Biotechnology

Vir Biotechnology, Inc, a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It offers tobevibart + elebsiran for the treatment of chronic hepatitis delta; elebsiran + PEG-IFN-a, tobevibart ± elebsiran ± PEG-IFN-a, and elebsiran+ TLR8+PD-1 for the treatment of chronic hepatitis B; VIR-1388 and Cure mAb combination for the treatment of human immunodeficiency virus; VIR-8190 for the treatment of respiratory syncytial virus / human metapneumovirus; VIR-2981 for the treatment of influenza; VIR-1949 for the treatment of pre-cancerous HPV lesions; and VIR07229 and Sotrovimab for the treatment of COVID-19 infection under the Xevudy brand.